|
T39957 |
CDK4/6-IN-6
|
|
CDK
|
|
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. |
|
T10736 |
CDK4/6-IN-2
|
|
CDK
|
|
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM). |
|
T39956 |
CDK4/6-IN-5
|
CDK4/6-IN-5 |
|
|
CDK4/6-IN-5 is a highly effective inhibitor of CDK4 and CDK6, with Ki values of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively (WO2019207463A1, example A93). |
|
T10737 |
CDK4/6-IN-3
|
|
CDK
|
|
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM. |
|
T10738 |
Abemaciclib metabolite M20
|
CDK4/6-IN-4,LSN3106726 |
CDK
|
|
Abemaciclib metabolite M20 (CDK4/6-IN-4) is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for researches on the treatment of cancer. |
|
T67780 |
AM5992
|
CDK4/6-IN-16 |
CDK
|
|
AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders. |
|
T60328 |
CDK4/6-IN-12
|
|
|
|
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity against CDK4 and CDK6 with IC 50 of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used in ... |
|
T72928 |
CDK4/6-IN-15
|
|
|
|
CDK4/6-IN-15, an orally active and selective inhibitor of CDK4/6, effectively halts the growth of cancer cells by arresting the cell cycle at the G1 phase and inhibiting the phosphorylation of the retinoblastoma tumor su... |
|
T62605 |
CDK4/6-IN-13
|
|
|
|
Compounds 10B and 10C, functioning as cdk4/6 inhibitors, demonstrated low nanomolar activity, optimal antiproliferative effects, excellent metabolic properties, and acceptable pharmacokinetics targeting cdk4/6. |
|
T62192 |
CDK4/6-IN-9
|
|
|
|
CDK4/6-IN-9 (compound 10) is a selective inhibitor of CDK4/6, capable of acting on CDK6/cyclin D1 (IC50: 905 nM). CDK4/6-IN-9 has potential research value in multiple myeloma (MM). |
|
T79112 |
CDK4/6-IN-17
|
|
CDK
|
|
CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells. It has shown efficacy in inhibiting tumor growth in the COLO205 x... |
|
T61892 |
CDK4/6-IN-8
|
|
|
|
CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM). |
|
T61738 |
CDK4/6-IN-7
|
|
|
|
CDK4/6-IN-7, a highly potent and selective orally active inhibitor of CDK4/6, demonstrates impressive inhibition activity with IC50 values of 1.58 nM and 4.09 nM respectively. This compound is particularly valuable for b... |
|
T74370 |
CDK4/6-IN-11
|
|
|
|
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader. |
|
T64244 |
CDK4/6-IN-10
|
|
|
|
CDK4/6-IN-10 is a selective, potent, orally active inhibitor of CDK4 (IC50: 22 nM) and CDK6 (IC50: 10 nM) with antitumour effects. CDK4/6-IN-10 has potential for studies in multiple myeloma (MM). |
|
T72951 |
CDK4/6-IN-14
|
|
|
|
CDK4/6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4/6), demonstrating inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It possesses over 60-fold greater selec... |
|
T36694 |
XY028-140
|
XY028-140 |
CDK
,
Ligand for E3 Ligase
|
|
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. |
|
T21720 |
GP-82996
|
Cdk4/6 Inhibitor IV,CINK4 |
CDK
|
|
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U... |
|
T75029 |
HEMTAC CDK4/6 degrader 1
|
|
|
|
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a K d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests c... |
|
T75127 |
CDK-IN-12
|
|
|
|
CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1]. |
|
T36967 |
LSN3106729 hydrochloride
|
|
|
|
LSN3106729 hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. LSN3106729 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1].
[1]. Edward S. Kim, et ... |
|
T35476 |
BSJ-04-132
|
|
|
|
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.
Jiang et al (2019) Development of dual and selective degraders of cyclin-dependent kinases 4... |
|
T63199 |
Dalpiciclib hydrochloride
|
|
|
|
Dalpiciclib (SHR-6390) hydrochloride is a highly selective, orally active CDK4/6 inhibitor with IC50 values of 12.4 nM and 9.9 nM, respectively, and is capable of acting as an antitumor agent in breast and esophageal squ... |
|
T79572 |
MAPK-IN-2
|
|
EGFR
|
|
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell lines. It demonstrates robust suppression of the MAPK pathway (E... |
|
T69196 |
AG-012986
|
|
|
|
AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activit... |
|
T69197 |
AG-012986 HCl
|
|
|
|
AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative... |
